174 related articles for article (PubMed ID: 17612567)
1. The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
Braumann C; Jacobi CA; Rogalla S; Menenakos C; Fuehrer K; Trefzer U; Hofmann M
J Surg Res; 2007 Dec; 143(2):372-8. PubMed ID: 17612567
[TBL] [Abstract][Full Text] [Related]
2. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery.
Da Costa ML; Redmond HP; Bouchier-Hayes DJ
J Surg Res; 2001 Dec; 101(2):111-9. PubMed ID: 11735264
[TBL] [Abstract][Full Text] [Related]
3. Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins.
Sun BS; Wang JH; Liu LL; Gong SL; Redmond HP
J Surg Oncol; 2007 Sep; 96(3):241-8. PubMed ID: 17469118
[TBL] [Abstract][Full Text] [Related]
4. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma.
Nici L; Monfils B; Calabresi P
Clin Cancer Res; 2004 Nov; 10(22):7655-61. PubMed ID: 15569998
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer.
Darnowski JW; Goulette FA; Cousens LP; Chatterjee D; Calabresi P
Cancer Chemother Pharmacol; 2004 Sep; 54(3):249-58. PubMed ID: 15173956
[TBL] [Abstract][Full Text] [Related]
6. Influence of intraperitoneal application of taurolidine/heparin on expression of adhesion molecules and colon cancer in rats undergoing laparoscopy.
Bobrich E; Braumann C; Opitz I; Menenakos C; Kristiansen G; Jacobi CA
J Surg Res; 2007 Jan; 137(1):75-82. PubMed ID: 17109891
[TBL] [Abstract][Full Text] [Related]
7. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent.
Calabresi P; Goulette FA; Darnowski JW
Cancer Res; 2001 Sep; 61(18):6816-21. PubMed ID: 11559556
[TBL] [Abstract][Full Text] [Related]
8. Wound healing is not impaired in rats undergoing perioperative treatment with the antineoplastic agent taurolidine.
Braumann C; Guenther N; Pohlenz J; Pfirrmann RW; Menenakos C
Eur Surg Res; 2009; 42(2):91-6. PubMed ID: 19088475
[TBL] [Abstract][Full Text] [Related]
9. High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats.
Braumann C; Stuhldreier B; Bobrich E; Menenakos C; Rogalla S; Jacobi CA
J Surg Res; 2005 Nov; 129(1):129-35. PubMed ID: 15916768
[TBL] [Abstract][Full Text] [Related]
10. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth.
Gil-Ad I; Shtaif B; Levkovitz Y; Nordenberg J; Taler M; Korov I; Weizman A
Oncol Rep; 2006 Jan; 15(1):107-12. PubMed ID: 16328041
[TBL] [Abstract][Full Text] [Related]
11. Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats.
Braumann C; Schoenbeck M; Menenakos C; Kilian M; Jacobi CA
Clin Exp Metastasis; 2005; 22(1):77-83. PubMed ID: 16132581
[TBL] [Abstract][Full Text] [Related]
12. Instillation of taurolidine/heparin after laparotomy reduces intraperitoneal tumour growth in a colon cancer rat model.
Opitz I; Van der Veen H; Witte N; Braumann C; Mueller JM; Jacobi CA
Eur Surg Res; 2007; 39(3):129-35. PubMed ID: 17337889
[TBL] [Abstract][Full Text] [Related]
13. Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo.
Abramjuk C; Bueschges M; Schnorr J; Jung K; Staack A; Lein M
Oncol Rep; 2009 Aug; 22(2):409-14. PubMed ID: 19578784
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
15. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism.
Han Z; Ribbizi I; Pantazis P; Wyche J; Darnowski J; Calabresi P
Anticancer Res; 2002; 22(4):1959-64. PubMed ID: 12174870
[TBL] [Abstract][Full Text] [Related]
16. Polymer conjugated bovine seminal ribonuclease inhibits growth of solid tumors and development of metastases in mice.
Soucek J; Poucková P; Zadinová M; Hlousková D; Plocová D; Strohalm J; Hrkal Z; Oleár T; Ulbrich K
Neoplasma; 2001; 48(2):127-32. PubMed ID: 11478693
[TBL] [Abstract][Full Text] [Related]
17. Leukopoiesis is not affected after intravenous treatment with the novel antineoplastic agent taurolidine. Results of an experimental study in rats.
Braumann C; Menenakos C; Atanassov V; Pfirrmann RW; Guenther N; Jacobi CA
Eur Surg Res; 2008; 40(4):341-6. PubMed ID: 18303270
[TBL] [Abstract][Full Text] [Related]
18. Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma.
Pierson HF; Meadows GG
Cancer Res; 1983 May; 43(5):2047-51. PubMed ID: 6831435
[TBL] [Abstract][Full Text] [Related]
19. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine.
Stendel R; Scheurer L; Stoltenburg-Didinger G; Brock M; Möhler H
Anticancer Res; 2003; 23(3B):2309-14. PubMed ID: 12894508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
